cBMSCs treated with OM expressed higher levels of Runx2, BMP, BSP, and BGLAP mRNA relative to non-treated control cells, indicating osteogenic differentiation of cBMSCs (Figure 6A). The gene discussed is RUNX2; the disease is ocular melanoma.